
PE anti-rat CD134 (OX-40)
CD134 (OX-40 receptor)is a 50 kd type I membrane protein, expressed on activated T cells.It binds to the OX-40 ligand (CD252) to provide a co-stimulatory signal that is independent of CD28.It is reported to block binding of CD134 and CD252.
PRODUCT DETAILS
Clone: OX-40
Antibody Type: Monoclonal
Reactivity: Rat
Format: PE
Host: Mouse
Isotype: IgG2b, κ
Applications: FC - Quality tested
Regulatory Status: RUO
Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.
Original: $260.00
-70%$260.00
$78.00PE anti-rat CD134 (OX-40)
CD134 (OX-40 receptor)is a 50 kd type I membrane protein, expressed on activated T cells.It binds to the OX-40 ligand (CD252) to provide a co-stimulatory signal that is independent of CD28.It is reported to block binding of CD134 and CD252.
PRODUCT DETAILS
Clone: OX-40
Antibody Type: Monoclonal
Reactivity: Rat
Format: PE
Host: Mouse
Isotype: IgG2b, κ
Applications: FC - Quality tested
Regulatory Status: RUO
Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
CD134 (OX-40 receptor)is a 50 kd type I membrane protein, expressed on activated T cells.It binds to the OX-40 ligand (CD252) to provide a co-stimulatory signal that is independent of CD28.It is reported to block binding of CD134 and CD252.
PRODUCT DETAILS
Clone: OX-40
Antibody Type: Monoclonal
Reactivity: Rat
Format: PE
Host: Mouse
Isotype: IgG2b, κ
Applications: FC - Quality tested
Regulatory Status: RUO
Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.









